Demand for FDA Action Amid Shuffle

“That’s an impossible bar to clear, writes Alex Brill, an economist with Matrix Global Advisors and a fellow at the American Enterprise Institute, in a new report sponsored by the PBM lobby Pharmaceutical Care Management Association.”

COVID-19 and Nursing Homes: National Updates and Early Evidence on the Second Wave

Evidence from the initial coronavirus outbreaks within the United States has shown that the fate of nursing home residents is tightly linked to the severity of the virus within the nursing home’s state. With a “second wave” of COVID-19 in many southern states and a host of policy changes, it is worth investigating whether the evidence suggests this vulnerable group is now better protected.

House Committee Calls for CMS Action on Biosimilars

“‘One of the ways to align these incentives would be for CMS, in particular the Center for Medicare & Medicaid Innovation, to launch a demonstration project, a shared savings program in Medicare Part B for biosimilars. This would reward physicians for increasing their utilization of biosimilars, which would both create that incentive for physicians and align that incentive with the desire of taxpayers to lower overall costs in the biologic spend category,’ [Alex Brill] said.”

The Evolving Opioid Crisis

As the COVID-19 pandemic has swept across our country and claimed more than 100,000 lives in a few short months, the opioid epidemic, which dates back to at least the early 2000s, has received less attention. But the toll of the opioid crisis in the United States remains enormous by any measure.